Trial Profile
Phase I Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab, and Irinotecan in Patients With Advanced Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary) ; Utomilumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 24 Feb 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 25 Feb 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.